Market Chatter: Pfizer Sells Entire Stake in Haleon for $3.24 Billion

MT Newswires Live03-19

Pfizer (PFE) has sold its stake in over-the-counter drug maker Haleon (HLN) for about 2.5 billion UK pounds ($3.24 billion) to institutional investors and Haleon itself, Reuters reported Wednesday, citing a bookrunner for the deal.

Pfizer sold the shares at a price of 3.85 pounds each, the report said.

Under the deal, Haleon, which makes Sensodyne, Panadol and Advil, agreed to buy back 44 million shares from Pfizer while institutional inventors bought 618 million shares, the report said.

Following Pfizer's divestment, BlackRock's (BLK) BlackRock Investment Management (UK) unit will be Haleon's largest shareholder with a more than 5% stake, the report said.

Pfizer and Haleon did not immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment